CTAD 2022 View overview page

Highlights from CTAD 2022

Prioritizing the mechanistic understanding of AD to improve treatments

Photobiomodulation: why target the brain and the gut?

Clinical implementations of AlzoSure Predict

Longitudinal clinical outcomes of tau-PET-positive individuals

APOE-targeted epigenome therapy for Alzheimer’s disease

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Limitations of [18F]flortaucipir tau-PET imaging

Promise of exosomal proteins as biomarkers in Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Lecanemab and what this means for the future treatment of Alzheimer’s disease